archive-com.com » COM » A » AGENDIA.COM

Total: 235

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Impact Study | Agendia
    G Jerusalem J Klaase F de Snoo L Stork Sloots L Dekker Vroling M Lutke Holzik March 31 2014 Aim To measure the impact of MammaPrint on adjuvant treatment decisions and to analyze the agreement in treatment decisions between hospitals from 4 European countries for the same patient cohort Methods Breast cancer patients were prospectively enrolled and MammaPrint was Continued Risk estimations and treatment decisions in early stage breast cancer Agreement among oncologists and the impact of the 70 gene signature Publication Name European Journal of Cancer Author s Drukker CA van den Hout HC Sonke GS Brain E Bonnefoi H Cardoso F Goldhirsch A Harbeck N Honkoop AH Koornstra RHT van Laarhoven HWM Portielje JEA Schneeweiss A Smorenburg CH Stouthard J Linn SC Schmidt MK February 13 2014 BACKGROUND Clinical decision making in patients with early stage breast cancer requires adequate risk estimation by medical oncologists This survey evaluates the agreement among oncologists on risk estimations and adjuvant systemic treatment AST decisions and the impact of adding the 70 gene Continued Categories Abstract Poster 18 Accreditation 1 BluePrint 9 Clinical Studies 8 ColoPrint 5 Cost Effectiveness 6 Development 8 Impact Study 2 MammaPrint 40 MINDACT 5 News 56 Predictive

    Original URL path: http://www.agendia.com/category/impact/ (2016-05-01)
    Open archived version from archive


  • MammaPrint | Agendia
    breast cancer i e the detection of slow growing tumors that would never have caused symptoms or death became more prevalent with the implementation of population based screening Only rough estimates have been made of the proportion of patients that are Continued Long term impact of the 70 gene signature on breast cancer outcome Publication Name Breast Cancer Research and Treatment Author s C A Drukker H van Tinteren M K Schmidt E J Th Rutgers R Bernards M J van de Vijver L J van t Veer January 21 2014 Several studies have validated the prognostic value of the 70 gene prognosis signature MammaPrintR but long term outcome prediction of these patients has not been previously reported The follow up of the consecutively treated cohort of 295 patients 53 years with invasive breast Continued MammaPrint Molecular Diagnostics on Formalin Fixed Paraffin Embedded Tissue Publication Name The Journal of Molecular Diagnostics Author s Sapino A Roepman P Linn SC Snel MHJ Delahaye LJMJ van den Akker J Glas AM Simon IM Barth N de Snoo FA van t Veer LJ Molinaro L Berns EMJJ Wesseling J Riley LB Anderson D Nguyen B Cox December 30 2013 MammaPrint a prognostic 70 gene profile for early stage breast cancer has been available for fresh tissue Improvements in RNA processing have enabled microarray diagnostics for formalin fixed paraffin embedded FFPE tissue Here we describe method optimization validation and performance of MammaPrint using Continued Performance Characteristics of the MammaPrint Breast Cancer Diagnostic Gene Signature Publication Name Personalized Medicine Author s Leonie JM Delahaye Diederik Wehkamp Arno N Floore Rene Bernards Laura J van t Veer1 Annuska M Glas November 1 2013 The analytical performance of multigene signatures depends on many parameters including precision repeatability reproducibility and intratumor heterogeneity Indicators such as sensitivity specificity positive predictive value and negative predictive value are typically used to define the clinical performance of a diagnostic Continued Molecular subtyping of early stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy Publication Name Breast Cancer Research and Treatment Author s Stefan Glück Femke de Snoo Justine Peeters Lisette Stork Sloots George Somlo June 1 2013 The aim of this study was to analyze the correlation between the pathologic complete response pCR rate after neoadjuvant chemotherapy and long term outcome distant metastases free survival DMFS in patients with early stage breast cancer using BluePrint and MammaPrint molecular subtyping versus Continued A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study Publication Name International Journal of Cancer Author s C A Drukker J M Bueno de Mesquita V P Retèl W H van Harten H van Tinteren J Wesseling R M H Roumen M Knauer L J van t Veer G S Sonke E J T Rutgers M J van de Vijver S C Linn January 31 2013 The 70 gene signature MammaPrint has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases

    Original URL path: http://www.agendia.com/category/mammaprint/ (2016-05-01)
    Open archived version from archive

  • MINDACT | Agendia
    BluePrint MammaPrint and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041 BIG 3 04 MINDACT trial Publication Name SABCS 2012 Poster Author s Giuseppe Viale Leen Slaets Femke de Snoo Laura J van t Veer Emiel J Rutgers Martine Piccart Jan Bogaerts Jeroen van den Akker Lisette Stork Sloots Kristel Engelen Leila Russo Patrizia Dell Orto Fatima Cardoso December 6 2012 Biology has become the main driver of breast cancer therapy Intrinsic biological subtypes by gene expression profiling have been identified Pathology can be used to define surrogates of these subtypes but these are not always concordant which may lead to Continued The EORTC 10041 BIG 03 04 MINDACT trial is feasible Results of the pilot phase Publication Name EUROPEAN JOURNAL OF CANCER Author s Emiel Rutgers Martine J Piccart Gebhart Jan Bogaerts Suzette Delaloge Laura Van t Veer November 1 2011 Background The MINDACT Microarray In Node negative and 1 3 node positive Disease may Avoid ChemoTherapy trial investigates the clinical utility of the 70 gene profile MammaPrint for the selection of breast cancer patients for adjuvant chemotherapy CT together with standard clinicopathological criteria Continued Daily clinical practice of fresh tumour tissue freezing and gene expression profiling logistics pilot study preceding the MINDACT trial Publication Name European Journal of Cancer Author s S Mook H Bonnefoi G Pruneric D Larsimont J Jaskiewicz M D Sabadell G MacGrogan L J van t Veer F Cardoso E J Rutgers February 14 2009 Purpose The 70 gene prognosis signature is a prognostic tool for early breast cancer analysis In addition to scientific evidence implementation of the signature in clinical trials and daily practice requires logistical feasibility The aim of our study was to test logistics Continued Clinical Application of the 70 Gene Profile The MINDACT Trial

    Original URL path: http://www.agendia.com/category/mindact/ (2016-05-01)
    Open archived version from archive

  • News | Agendia
    diagnostics announced Continued Agendia Statement in Response to Recent ASCO Guidelines on Biomarker Assay Use in Adjuvant Breast Cancer Care February 11 2016 Agendia is disappointed with the recent update to the American Society of Clinical Oncology ASCO Clinical Practice Guidelines and with the decision to move forward without key research that we feel would have a material effect on the guidelines We Continued Agendia and Partners Receive 6 8 million from European Commission to Study Targeted Therapies for Colorectal Cancer December 16 2015 IRVINE CA and AMSTERDAM THE NETHERLANDS Agendia Inc and several European partners have received a 6 8 million European Commission grant to study targeted therapies for colorectal cancer CRC The grantees will test therapies matched to the molecular subtype of Continued Agendia s MammaPrint and BluePrint Breast Cancer Tests to Be Highlighted at San Antonio Symposium December 7 2015 Satellite Symposium and Dinner Presentation Will Offer Latest Insights on Genomic Testing and Molecular Subtyping IRVINE CA and AMSTERDAM THE NETHERLANDS New breast cancer research highlighting the value of Agendia s MammaPrint and BluePrint genomic tests will be presented in 10 Continued Agendia Highlights Study Showing MammaPrint BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens September 29 2015 Researchers Present Data at Breast Cancer Symposium Showing MammaPrint BluePrint Can Identify Women Who Benefit from Chemotherapy and Targeted Dual Anti HER2 Drug Treatment Before Surgery IRVINE CA and AMSTERDAM THE NETHERLANDS Agendia s MammaPrint and BluePrint tests provide new insights that may provide many Continued Agendia Board of Directors Appoints Mark R Straley as New Chief Executive Officer September 28 2015 IRVINE CA and AMSTERDAM Agendia Inc a world leader in personalized medicine and molecular cancer diagnostics today announced the appointment of veteran diagnostics industry leader Mark R Straley as Chief Executive Officer

    Original URL path: http://www.agendia.com/category/news/ (2016-05-01)
    Open archived version from archive

  • Predictive | Agendia
    predict long term survival and chemotherapy response on the same patient cohort and assess if clinicopathological variables carry independent prognostic and predictive values We Continued The predictive value of the 70 gene signature for adjuvant chemotherapy in early breast cancer Publication Name Breast Cancer Research and Treatment Author s Michael Knauer Stella Mook Emiel J T Rutgers Richard A Bender Michael Hauptmann Marc J van de Vijver Rutger H T Koornstra Jolien M Bueno de Mesquita Sabine C Linn Laura J van t Veer March 5 2010 Multigene assays have been developed and validated to determine the prognosis of breast cancer In this study we assessed the additional predictive value of the 70 gene MammaPrint signature for chemotherapy CT benefit in addition to endocrine therapy ET from pooled Continued Prediction of adjuvant chemotherapy benefit in endocrine responsive early breast cancer using multigene assays Publication Name The Breast Author s Kathy S Albain Soonmyung Paik Laura van t Veer January 1 2009 Background Multigene assays performed on the primary tumors from women with non metastatic breast cancer provide useful prognostic information and discriminate excellent versus poor outcome potential in diverse clinical scenarios Recently analyses were conducted to determine if these assays

    Original URL path: http://www.agendia.com/category/predictive/ (2016-05-01)
    Open archived version from archive

  • Press Release | Agendia
    cancer diagnostics announced Continued Agendia Statement in Response to Recent ASCO Guidelines on Biomarker Assay Use in Adjuvant Breast Cancer Care February 11 2016 Agendia is disappointed with the recent update to the American Society of Clinical Oncology ASCO Clinical Practice Guidelines and with the decision to move forward without key research that we feel would have a material effect on the guidelines We Continued Agendia and Partners Receive 6 8 million from European Commission to Study Targeted Therapies for Colorectal Cancer December 16 2015 IRVINE CA and AMSTERDAM THE NETHERLANDS Agendia Inc and several European partners have received a 6 8 million European Commission grant to study targeted therapies for colorectal cancer CRC The grantees will test therapies matched to the molecular subtype of Continued Agendia s MammaPrint and BluePrint Breast Cancer Tests to Be Highlighted at San Antonio Symposium December 7 2015 Satellite Symposium and Dinner Presentation Will Offer Latest Insights on Genomic Testing and Molecular Subtyping IRVINE CA and AMSTERDAM THE NETHERLANDS New breast cancer research highlighting the value of Agendia s MammaPrint and BluePrint genomic tests will be presented in 10 Continued Agendia Highlights Study Showing MammaPrint BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens September 29 2015 Researchers Present Data at Breast Cancer Symposium Showing MammaPrint BluePrint Can Identify Women Who Benefit from Chemotherapy and Targeted Dual Anti HER2 Drug Treatment Before Surgery IRVINE CA and AMSTERDAM THE NETHERLANDS Agendia s MammaPrint and BluePrint tests provide new insights that may provide many Continued Agendia Board of Directors Appoints Mark R Straley as New Chief Executive Officer September 28 2015 IRVINE CA and AMSTERDAM Agendia Inc a world leader in personalized medicine and molecular cancer diagnostics today announced the appointment of veteran diagnostics industry leader Mark R Straley as Chief Executive

    Original URL path: http://www.agendia.com/category/press-release/ (2016-05-01)
    Open archived version from archive

  • Publications | Agendia
    2014 Background Cost effectiveness analysis of MammaPrint 70 gene signature in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy Methods Markov model assuming a cohort of 60 year old women with breast cancer Continued Chemosensitivity predicted by BluePrint 80 gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial NBRST Publication Name Annals of Surgical Oncology Author s Whitworth P Stork Sloots L de Snoo FA Richards P Rotkis M Beatty J Mislowsky A Pellicane JV Nguyen B Lee L Nash C Gittleman M Akbari S Beitsch PD October 21 2014 PURPOSE The purpose of the NBRST study is to compare a multigene classifier to conventional immunohistochemistry IHC fluorescence in situ hybridization FISH subtyping to predict chemosensitivity as defined by pathological complete response pCR or endocrine sensitivity as defined by partial response Continued European Inter Institutional Impact Study of MammaPrint Publication Name The Breast Author s P G Cusumano D Generali E Ciruelos L Manso I Ghanem E Lifrange G Jerusalem J Klaase F de Snoo L Stork Sloots L Dekker Vroling M Lutke Holzik March 31 2014 Aim To measure the impact of MammaPrint on adjuvant treatment decisions and to analyze the agreement in treatment decisions between hospitals from 4 European countries for the same patient cohort Methods Breast cancer patients were prospectively enrolled and MammaPrint was Continued Risk estimations and treatment decisions in early stage breast cancer Agreement among oncologists and the impact of the 70 gene signature Publication Name European Journal of Cancer Author s Drukker CA van den Hout HC Sonke GS Brain E Bonnefoi H Cardoso F Goldhirsch A Harbeck N Honkoop AH Koornstra RHT van Laarhoven HWM Portielje JEA Schneeweiss A Smorenburg CH Stouthard J Linn SC Schmidt MK February 13 2014 BACKGROUND Clinical decision making in patients with early stage breast cancer requires adequate risk estimation by medical oncologists This survey evaluates the agreement among oncologists on risk estimations and adjuvant systemic treatment AST decisions and the impact of adding the 70 gene Continued Mammographic screening detects low risk tumor biology breast cancers Publication Name Breast Cancer Research and Treatment Author s Drukker CA Schmidt MK Rutgers EJT Cardoso F Kerlikowske K Esserman LJ van Leeuwen FE Pijnappel RM Slaets L Bogaerts J Van t Veer LJ January 28 2014 Overdiagnosis of breast cancer i e the detection of slow growing tumors that would never have caused symptoms or death became more prevalent with the implementation of population based screening Only rough estimates have been made of the proportion of patients that are Continued Long term impact of the 70 gene signature on breast cancer outcome Publication Name Breast Cancer Research and Treatment Author s C A Drukker H van Tinteren M K Schmidt E J Th Rutgers R Bernards M J van de Vijver L J van t Veer January 21 2014 Several studies have validated the prognostic value of the 70 gene prognosis signature MammaPrintR

    Original URL path: http://www.agendia.com/category/publications/ (2016-05-01)
    Open archived version from archive

  • Review Article | Agendia
    Expression profiling Decoding breast cancer Publication Name Surgical Oncology Author s deSnoo F Bender R Glas G and Rutgers E December 31 2009 Gene expression assays that are used in daily clinical practice for treating early breast cancer patients have been introduced in the clinic only recently This review discusses the development of these arrays summarizes the validation of those that are commercially Continued MammaPrint the 70 gene signature another milestone in personalized medical care for breast cancer patients Publication Name Expert Review Diagnostic Profile Author s EA Slodkowska and JS Ross January 1 2009 The MammaPrint assay Agendia BV The Netherlands is the first fully commercialized microarray based multigene assay designed to individualize treatment for patients with breast cancer MammaPrint the first assay to be cleared at the 510 k level by the US FDA s new in Continued Enabling personalized cancer medicine through analysis of gene expression patterns Publication Name Nature Author s Laura J van t Veer René Bernards January 1 2008 Therapies for patients with cancer have changed gradually over the past decade moving away from the administration of broadly acting cytotoxic drugs towards the use of more specific therapies that are targeted to each tumour To facilitate this shift tests Continued Mammary gland biology and breast cancer Conference on Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer Progression Publication Name EMBO Reports Author s Sharon F McGee Fiona Lanigan Emer Gilligan and Bernd Groner October 20 2006 Introduction As a model system for biological investigations the mouse mammary gland is as versatile as the Drosophilaeye This comparison does not reflect any ignorance of comparative anatomy but rather it highlights the multitude of possibilities that the mammary gland Continued Microarray analysis and tumor classification Publication Name New England Journal of Medicine Author s J

    Original URL path: http://www.agendia.com/category/review-article/ (2016-05-01)
    Open archived version from archive



  •